A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Elizabeth A. Raetz(NYU Langone Health), William L. Carroll(NYU Langone Health), Eleny Romanos‐Sirakis(Staten Island University Hospital), Aby Buchbinder(Enzon Pharmaceuticals (United States)), Deepa Bhojwani(St. Jude Children's Research Hospital), Jeannette Cassar(Children's Hospital of Los Angeles), Elena Eckroth(Children's Hospital of Los Angeles), Paul S. Gaynon(University of Southern California), Richard Sposto(Children's Hospital of Los Angeles), Jemily Malvar(University of Southern California), Bruce Bostrom(Minnesota West Community & Technical College), D. Morrison(NYU Langone Health), Patrick A. Brown(Haemonetics (United States))
Cited by 41
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934